去年，中国国产疫苗在海外市场实现了超过3亿美元的销售额，这一数据彰显了中国生物医药产业的全球影响力与竞争力。在全球新冠疫情持续蔓延的背景下，中国疫苗凭借其安全性、有效性和可及性，获得了多个国家和国际组织的认可。例如，国药集团（Sinopharm）和科兴生物（Sinovac）的疫苗产品被广泛出口至亚洲、非洲、拉丁美洲等地区，助力当地疫情防控。这一成绩不仅推动了中国与全球各国的卫生合作，也为“健康丝绸之路”倡议提供了实质支持。未来，随着产能提升和国际认证进程加速，中国疫苗有望进一步拓展海外市场，为全球公共卫生事业作出更大贡献。
Last year, Chinese-made vaccines achieved over USD 300 million in overseas sales, highlighting the global influence and competitiveness of China’s biopharmaceutical industry. Amid the ongoing COVID-19 pandemic, Chinese vaccines have gained recognition from multiple countries and international organizations due to their safety, efficacy, and accessibility. For instance, vaccines from Sinopharm and Sinovac were widely exported to regions such as Asia, Africa, and Latin America, supporting local epidemic control efforts. This accomplishment not only promotes health cooperation between China and the world but also provides substantial support for the “Health Silk Road” initiative. With increasing production capacity and accelerated international certification, Chinese vaccines are expected to further expand their global presence and contribute more to worldwide public health in the future.
原创文章，作者：admin，如若转载，请注明出处：https://ktez.cn/24309.html